Debra R. Lappin

Principal - Science & Regulatory Policy - Faegre Drinker Consulting


Debra Lappin leads complex partnering and coalition strategies across the life sciences enterprise. She is recognized across government, nonprofit, academic and industry sectors for her ability to drive public health and science policy strategies that advance mission and business purposes, all with a common aim of improving human health. She leads Faegre Drinker Consulting’s health and biosciences team.

Drug Development, Patient Data and Clinical Trials

Debra is a subject matter authority in regulatory science, where she leads initiatives for patient engagement in drug development and in the generation of value models for payment and coverage determinations. She advises on new tools and collaborations to deliver patient data and patient insights to inform and enable clinical development and access, including: clinical trial design, endpoint confirmation, regulatory submissions and labeling, development of real world evidence, and benefit design. Drawing upon her understanding of health agency trends, law, ethics and practical funding challenges, Debra delivers advice and creative solutions that position clients to take advantage of the “future state” in the federal enterprise.

Strategic Communications

Debra facilitates scientific meetings, bringing an ability to translate and synthesize complex scientific information for diverse audiences and to elicit collective and balanced input. She is respected and trusted by senior leaders across the nation’s health agencies, having served on advisory boards to the directors of both the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), as President of the Council for American Medical Innovation, and continuing today as a member of the Board of Research!America.

Debra serves clients of Faegre Drinker Consulting as a consulting professional, and does not act as a lawyer for those clients. Learn more.




Insights & Events

Other Perspectives
  • Patient Engagement in Alzheimer’s Drug Development: Disruptive Innovation
    Alzheimer’s Association International Conference, Toronto, July 2016
  • Time = Lives: Resiliency – The Potent Ingredient in the Path to Better Health
    Milken Partnering for Cures, New York City, November 2015
  • The Role of the Indiana CTSI: Impacting the Life Sciences Sector, Translating Science Into Therapies
    Co-presenter, BioCrossroads Frameworx, Indianapolis, November 12, 2015

Leadership & Community

Professional Associations

  • Council for American Medical Innovation — President
  • Research!America — Board Member
  • Centers for Disease Control and Prevention (CDC) — Former Advisory Committee to the Director
  • National Institutes of Health (NIH) — Former Committee on Organizational Structure
  • Arthritis Foundation — Former National Chair and Trustee Emeritus
  • National Library of Medicine — Former PubMed Central Advisory Committee
  • National Institutes of Health Counsel of Public Representatives — Charter Member
  • Institute of Medicine — Former Committee on National Immunization Policy Data Sharing
The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.